The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.
 
Wenxin Xu
No Relationships to Disclose
 
Maheetha Bharadwaj
No Relationships to Disclose
 
Grace Birch
No Relationships to Disclose
 
Nicholas Schindler
No Relationships to Disclose
 
Chris Labaki
Research Funding - Roche/imCORE
 
Renee Maria Saliby
No Relationships to Disclose
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Dory Freeman
No Relationships to Disclose
 
Jillian O'Toole
No Relationships to Disclose
 
Gwo-Shu Mary Lee
No Relationships to Disclose
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Michelle S. Hirsch
Consulting or Advisory Role - Janssen; UpToDate
 
Sachet A. Shukla
Stock and Other Ownership Interests - Agenus; Agios; BreakBio Corp.; Bristol Myers Squibb; Lumos Pharma
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; AVEO; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; Synthekine; Werewolf Therapeutics
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI
 
Rizwan Romee
Honoraria - Jacobio; Miltenyi Biotec
Research Funding - Crispr Therapeutics; Skyline Therapeutics
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; ESMO; KidneyCan; NCCN
Stock and Other Ownership Interests - Osel; Pionyr; Precede Bio; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Aveo; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; IQvia; Janssen Oncology; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NCI Genitourinary Cancers Steering Committee; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Infinity Pharmaceuticals; Ipsen; Kanaph Therapeutics; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Nuscan Diagnostics; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GATEWAY for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
David A. Braun
Honoraria - LM Education/Exchange Service
Consulting or Advisory Role - Adept Field Solutions; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Charles River Associates; Dedham Group; Defined Health; Exelixis; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Trinity Group
Travel, Accommodations, Expenses - Bristol-Myers Squibb